Source comparison
TB-500 Support Injury Prevention Research: Type Comparison
Equine tendon repair Post-injury (induced lesions) Tensile strength recovery at 12 weeks 28% improvement vs control Strong evidence. Actin pathways activated by damage Rodent dermal wound closure Post-injury (full-thickness excision) Days to complete re-epithe
This comparison does not assign a generated winner or score.
- Equine tendon repair
- Post-injury (induced lesions)
- Tensile strength recovery at 12 weeks
- 28% improvement vs control
- Strong evidence. Actin pathways activated by damage
- Rodent dermal wound closure
- Post-injury (full-thickness excision)
- Days to complete re-epithelialization
- 40–60% faster closure
- Consistent across multiple labs. Reproducible
- Equine prophylactic administration
- Pre-injury (intact tendons)
- Injury incidence during exercise stress
- No significant difference vs placebo
- Prevention hypothesis unsupported
- Human Achilles tendinopathy case series
- Chronic injury (existing damage)
- Pain reduction + ultrasound markers
- Modest improvement. No control group
- Suggestive but uncontrolled. High bias risk
- Human Phase I safety (Tβ4, not TB-500)
- Acute myocardial infarction
- Safety + exploratory cardiac function
- Well tolerated. Functional data inconclusive
- Safety established. Efficacy not demonstrated